동결건조 주사제 시장 규모 : 약제 유형, 적응증, 포장 유형, 유통 채널, 약물전달 유형별, 세계 예측(2023-2032년)

Global Lyophilized Injectable Drugs Market will witness a 13.5% CAGR between 2023 and 2032. The continuous R&D efforts by the pharmaceutical industry are leading to an increasing number of biological drugs that require lyophilization for stability and longer shelf life. These drugs, including vaccines and monoclonal antibodies, are vital in treating various diseases, thereby boosting the market.

The global demand for personalized medicine is rising, necessitating the production of lyophilized drugs that can be easily reconstituted for individualized treatment regimens. Furthermore, the ever-expanding field of oncology relies heavily on lyophilized drugs for chemotherapy and targeted therapies, intensifying market growth.

As the pharmaceutical and biotechnology sectors continue to advance in research and development activities, the lyophilized injectable drugs market outlook will strengthen over 2023-2032. For instance, in August 2023, Revive Therapeutics, a specialized life sciences company, commenced work on a fresh formulation of Bucillamine. Revive initiated a sponsored research collaboration with the University of Waterloo to develop an innovative lyophilized Bucillamine injectable formulation. This research focuses on meeting the needs of public health emergencies.

The overall Lyophilized Injectable Drugs industry is classified based on drug type, indication, packaging type, distribution channel, and region.

By drug type, the anti-neoplastics segment will witness a 13.3% CAGR from 2023 to 2032. Anti-neoplastic drugs used in cancer treatment often require lyophilization to maintain their stability and efficacy. This process enables these drugs to be stored for longer periods without losing potency. As cancer remains a global health challenge, and with advancements in oncology therapies, the lyophilized injectable drugs market demand in the anti-neoplastics segment continues to grow.

Regarding the packaging type, the prefilled devices segment will augment significantly from 2023 to 2032. These devices offer convenience and accuracy in drug delivery, making them particularly appealing for lyophilized injectable drugs. Prefilled syringes and other delivery systems ensure precise dosing and reduce the risk of contamination, enhancing patient safety and compliance. Additionally, healthcare professionals appreciate the ease of administration.

By indication, the respiratory diseases segment will register a 12% CAGR from 2023 to 2032. Many therapies for respiratory ailments, including severe asthma and chronic obstructive pulmonary disease (COPD), are delivered through lyophilized injectables. Lyophilization ensures the stability and shelf life of these drugs while preserving their potency. With the global prevalence of respiratory diseases on the rise, the overall share of the lyophilized injectable drugs market in this therapeutic area is growing.

By distribution channel, the hospital pharmacies segment will exhibit a high growth rate from 2023 to 2032. These medications offer advantages such as extended shelf life, stability, and ease of reconstitution, making them essential for timely and efficient patient care. Hospital pharmacies rely on lyophilized drugs for various critical applications, from emergency treatments to specialized therapies. Thus, hospital pharmacies contribute greatly to the lyophilized injectable drugs market revenue.

Regionally, Europe lyophilized injectable drugs industry will showcase a commendable CAGR from 2023 to 2032. European healthcare systems emphasize safety, quality, and precision in patient care, and lyophilized drugs align perfectly with these priorities. These drugs ensure stability, longer shelf life, and ease of administration, meeting the stringent regulatory standards in the region. With an aging population and growing healthcare needs, the demand for these drugs in Europe continues to grow.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Global lyophilized injectable drugs market 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Drug type trends
  • 2.1.4 Indication trends
  • 2.1.5 Type of delivery trends
  • 2.1.6 Packaging trends
  • 2.1.7 Distribution channel trends

Chapter 3 Lyophilized Injectable Drugs Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases globally
    • 3.2.1.2 Growing research and development activities in the industry
    • 3.2.1.3 Increasing number of product approvals for lyophilized injectable drugs
    • 3.2.1.4 Technological advancements in lyophilized injectable drugs delivery system
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Substantial number of product recalls of lyophilized drugs
    • 3.2.2.2 High costs associated with the manufacturing process
• 3.3 Growth potential analysis
  • 3.3.1 By drug type
  • 3.3.2 By indication
  • 3.3.3 By type of delivery
  • 3.3.4 By packaging
  • 3.3.5 By distribution channel
• 3.4 COVID- 19 impact analysis
• 3.5 Regulatory landscape
  • 3.5.1 U.S.
  • 3.5.2 Europe
• 3.6 Technology landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Patent landscape, 2022
  • 3.9.1 Top 10 patented lyophilized injectable drugs

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Company positioning matrix
• 4.4 Competitive analysis of major market players
• 4.5 Strategic outlook matrix
• 4.6 Strategy dashboard, 2022

Chapter 5 Lyophilized Injectable Drugs Market Size and Forecast, By Drug type (USD Million)

• 5.1 Key trends, by drug type
• 5.2 Anti-infectives
• 5.3 Anti-neoplastics
• 5.4 Anticoagulants
• 5.5 Hormones
• 5.6 Antiarrhythmics
• 5.7 Other drug types

Chapter 6 Lyophilized Injectable Drugs Market Size and Forecast, By Indication (USD Million)

• 6.1 Key trends, by indication
• 6.2 Autoimmune diseases
• 6.3 Respiratory diseases
• 6.4 Gastrointestinal disorders
• 6.5 Oncology
• 6.6 Cardiovascular diseases
• 6.7 Infectious diseases
• 6.8 Metabolic disorders
• 6.9 Other indications

Chapter 7 Lyophilized Injectable Drugs Market Size and Forecast, By Type of Delivery (USD Million)

• 7.1 Key trends, by type of delivery
• 7.2 Prefilled diluent syringes
• 7.3 Multi-step devices

Chapter 8 Lyophilized Injectable Drugs Market Size and Forecast, By Packaging (USD Million)

• 8.1 Key trends, by packaging
• 8.2 Vials
• 8.3 Cartridges
• 8.4 Prefilled devices

Chapter 9 Lyophilized Injectable Drugs Market Size and Forecast, By Distribution Channel (USD Million)

• 9.1 Key trends, by distribution channel
• 9.2 Hospital pharmacy
• 9.3 Retail pharmacy
• 9.4 Online pharmacy

Chapter 10 Lyophilized Injectable Drugs Market Size and Forecast, By Region (USD Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Belgium
  • 10.3.7 Netherlands
  • 10.3.8 Norway
  • 10.3.9 Switzerland
  • 10.3.10 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Indonesia
  • 10.4.7 New Zealand
  • 10.4.8 Singapore
  • 10.4.9 Thailand
  • 10.4.10 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Chile
  • 10.5.5 Colombia
  • 10.5.6 Rest of Latin America
• 10.6 Middle East & Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Egypt
  • 10.6.5 Iran
  • 10.6.6 Rest of Middle East & Africa

Chapter 11 Company Profiles

• 11.1 Bristol Myers Squibb
• 11.2 Gilead Sciences, Inc.
• 11.3 Cipla Limited
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Novo Nordisk A/S
• 11.6 Sanofi
• 11.7 Aurobindo Pharmaceuticals
• 11.8 Fresenius SE & Co. KGaA (Fresenius Kabi)
• 11.9 Merck & Co., Inc
• 11.10 Zydus Group
• 11.11 Vetter Pharma
• 11.12 Takeda Pharmaceutical Company Limited
• 11.13 Johnson & Johnson Services, Inc.